Lushang Freda Pharmaceutical Faces Valuation Challenges Amid Declining Financial Performance

Lushang Freda Pharmaceutical Co., Ltd., operating in the realty sector, has recently undergone an adjustment in its evaluation. This revision reflects notable shifts in its financial metrics and market position. The company's valuation grade has been categorized as very expensive, with a P/E ratio of 27 and a price-to-book value of 1.18. Additionally, the EV to EBIT stands at 13.58, while the EV to EBITDA is recorded at 7.96. The technical indicators present a mixed picture, with the MACD showing a mildly bullish trend on a weekly basis but bearish on a monthly scale. The moving averages indicate a mildly bearish sentiment, and the Bollinger Bands also reflect a similar trend. The company's return on equity (ROE) is at 4.40%, suggesting challenges in profitability relative to shareholders' funds. Long-term growth prospects appear constrained, as evidenced by a decline in net sales and operating profit over the past five years. The company has faced negative financial performance recently, with net sales hitting a low of CNY 807.27 million in the latest quarter. For those interested in further insights, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.